Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation
Hung D. Nguyen, … , Shikhar Mehrotra, Xue-Zhong Yu
Hung D. Nguyen, … , Shikhar Mehrotra, Xue-Zhong Yu
Published March 7, 2016
Citation Information: J Clin Invest. 2016;126(4):1337-1352. https://doi.org/10.1172/JCI82587.
View: Text | PDF
Research Article Immunology

Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation

  • Text
  • PDF
Abstract

Alloreactive donor T cells are the driving force in the induction of graft-versus-host disease (GVHD), yet little is known about T cell metabolism in response to alloantigens after hematopoietic cell transplantation (HCT). Here, we have demonstrated that donor T cells undergo metabolic reprograming after allogeneic HCT. Specifically, we employed a murine allogeneic BM transplant model and determined that T cells switch from fatty acid β-oxidation (FAO) and pyruvate oxidation via the tricarboxylic (TCA) cycle to aerobic glycolysis, thereby increasing dependence upon glutaminolysis and the pentose phosphate pathway. Glycolysis was required for optimal function of alloantigen-activated T cells and induction of GVHD, as inhibition of glycolysis by targeting mTORC1 or 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) ameliorated GVHD mortality and morbidity. Together, our results indicate that donor T cells use glycolysis as the predominant metabolic process after allogeneic HCT and suggest that glycolysis has potential as a therapeutic target for the control of GVHD.

Authors

Hung D. Nguyen, Shilpak Chatterjee, Kelley M.K. Haarberg, Yongxia Wu, David Bastian, Jessica Heinrichs, Jianing Fu, Anusara Daenthanasanmak, Steven Schutt, Sharad Shrestha, Chen Liu, Honglin Wang, Hongbo Chi, Shikhar Mehrotra, Xue-Zhong Yu

×

Figure 1

Donor T cells preferentially increase glycolysis in response to alloantigens in vivo.

Options: View larger image (or click on image) Download as PowerPoint
Donor T cells preferentially increase glycolysis in response to alloanti...
Lethally irradiated B6, B6D2F1 (1,100 cGy), or BALB/c (700 cGy) mice were transplanted with 5 × 106/mouse TCD-BM plus 1–2 × 106/mouse T cells isolated from B6 donors. After 14 days, recipients were euthanized, and blood and organs were collected. (A and B) The GVHD clinical score (A) and body weight loss (B) during experimental time course are shown. (C) Pathological score are indicated in recipient skin, liver, lung, small intestine (S.I.), and large intestine (L.I.). (D) Cytokine levels in the recipient sera are displayed. T cells were isolated from spleens or livers of the syngeneic or allogeneic recipients and measured for ECAR and OCR. (E and F) Summary of ECAR (E) or OCR (F) rate of T cells from recipient spleen or liver on day 14 after BMT. (A–D) Data were representative of three experiments (n = 7–10 per group). (E and F) The data were combined from three independent experiments (n = 15 per group). Bar graph shows the mean ± SEM. *P < 0.05; ***P < 0.001, Mann-Whitney U test (A and B), two-tailed Student t test (C–F).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts